UPDATE: Qiagen Revenues up 3 Percent in Q2; Plans $100M Stock Buyback | GenomeWeb

The story has been updated to include comments from Qiagen's conference call this morning.

NEW YORK (GenomeWeb News) – Qiagen reported after the close of the market on Tuesday that revenues for its second quarter increased 3 percent year over year at a constant exchange rate.

The company also announced a new share buyback program of up to $100 million. Based on the closing price of its stock on July 29, that would represent approximately 5 million shares, Qiagen said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?